We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Proteomics International Laboratories Launches $6m IPO


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteomics International Laboratories Launches $6m IPO"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Emerging life science company Proteomics International Laboratories Ltd  is pleased to announce that it has launched its prospectus for a new IPO to raise up to $6 million via the issue of 30 million shares at 20c each.

The minimum subscription amount is $4 million.

PIQ is a specialist technology-driven life sciences company founded in 2001 and based in Perth, Australia. It is an established, revenue generating business with a focus on the area of proteomics, and has generated gross income of $7.5 million to date.

The Company’s business model is based on its proprietary technology platform which operates across three synergistic business units in massive growth markets;

1. Analytical services - Specialist contract research, analytical testing and consultancy - fee for service model. Proteomics market estimated to be worth $20.8b by 2018.

2. Diagnostics - Biomarkers of disease and personalised medicine - focus on diabetic kidney disease and Alzheimer's disease. Biomarkers market estimated to be worth $40.8b by 2018.

3. Therapeutics - Peptide drug discovery from venoms with a focus on painkillers and antibiotics. Peptide therapeutics market currently estimated to be worth $17b.

The synergy arises from PIQ’s technology platform, which can be applied to each unit simultaneously. The output from each can feed development and growth in the others. This maximises the opportunity for the Company to use its resources to generate revenue and create new intellectual property - which in turn can be sold, licensed, or retained to generate further revenues.

The proceeds of the IPO will be used to expand and accelerate the growth of each business unit.

Advertisement